Bioengineering Program, Department of Mechanical Engineering, University of Michigan-Dearborn, Dearborn, Michigan, USA.
Amgen Bioprocessing Center, Henry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, California, USA.
Biotechnol J. 2024 Feb;19(2):e2300474. doi: 10.1002/biot.202300474.
Mesenchymal stem cell (MSC) derived exosomes have emerged as potential acellular therapeutics for various tissue regenerative applications. However, successful clinical translation of exosome-based therapy is limited by lack of a structured production platform. Thus, in this study, the effect of decellularized extracellular matrix (dECM) was assessed on the production and potency of exosomes secreted by bone marrow-derived human MSCs. The results indicate that there was a ∼2-fold increase in MSC-exosome production when MSCs were cultured on dECM compared to TCP. Further, our study revealed that dECM generation induced by ascorbic acid (AA) up to 100 µg mL highly increased exosome yield thereby indicating a potential scale up method for MSC exosome production. The bioactivity of exosomes was investigated by their ability to improve the healing of wounded human skin explants. Wound closure was enhanced in the presence of exosomes isolated from MSCs cultured on ascorbic acid-induced dECM compared to TCP generated MSC-exosomes. In summary, this study suggests a promising solution to a major bottleneck in large-scale production of MSC exosomes for cell-free therapy.
间充质干细胞(MSC)衍生的外泌体作为各种组织再生应用的潜在无细胞治疗方法已经出现。然而,外泌体治疗的成功临床转化受到缺乏结构化生产平台的限制。因此,在这项研究中,评估了去细胞细胞外基质(dECM)对骨髓来源的人 MSC 分泌的外泌体的产生和效力的影响。结果表明,与 TCP 相比,当 MSC 在 dECM 上培养时,MSC-外泌体的产生增加了约 2 倍。此外,我们的研究表明,由抗坏血酸(AA)诱导的 dECM 生成高达 100μg mL 可极大地增加外泌体产量,从而表明了 MSC 外泌体生产的潜在扩大方法。通过外泌体促进人皮肤碎片愈合的能力来研究外泌体的生物活性。与 TCP 生成的 MSC-外泌体相比,在存在从在抗坏血酸诱导的 dECM 上培养的 MSC 分离的外泌体的情况下,伤口闭合得到了增强。总之,这项研究为无细胞治疗用 MSC 外泌体的大规模生产提供了一个有前途的解决方案,解决了一个主要的瓶颈问题。